IMNM

Price (1 year)

Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.

Recent Form 4

Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.

Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.

Congressional trades

STOCK Act disclosures (90-day window)

Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.

No STOCK Act disclosures for this company in this window.

Signal

Neutral signalScored 2026-08-14 Drivers: fundamentals. Insiders: neutral. Moteurs : fondamentaux. Initiés : neutre.

IMNM presents a structurally fragile investment case: despite adequate liquidity (score 85), the near-zero fundamental trend score (15) reflects a pre-revenue, cash-burning operation with no credible near-term path to…

The first sentence of the analysis written for IMNM on 2026-08-14 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.

Market snapshot

Financial ratios

Sparkline shows each ratio oldest → newest (left → right).

How the latest year compares

For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower

Key metrics

Change by theme

Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.

Change over 1 year

Change over 5 years

Employee count

Peer market caps

Recent news

• 2026-08-17 argenx VYVGART Hits Phase III Goal in Autoimmune Myositis, Eyes IMNM Filing argenx NASDAQ: ARGX reported positive top-line results from its Phase III ALKIVIA trial of VYVGART Hytrulo in autoimmune myositis, meeting its primary endpoint in a combined population of patients with immune-mediated necrotizing myopathy, or IMNM, and dermatomyositis, or DM.
• 2026-08-17 argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis Study met primary endpoint of mean Total Improvement Score (TIS) at Week 52 in the combined study population of IMNM and DM patients (p=0.0011) Patient improvements observed early and sustained throughout study; consistent treatment effect across IMNM and DM First Phase 3 study to show statistically significant and clinically meaningful improvements in disease activity in IMNM, a subtype with no approved therapy argenx to host a conference call on August 17 th at 2:30 PM CET/ 8:30 AM ET August 17, 2026, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced positive topline results from the ALKIVIA Phase 3 study evaluating VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in adults with autoimmune myositis. Study met its primary endpoint (p=0.0011) In the combined immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM) population, patients treated with efgartigimod demonstrated statistically significant and clinically meaningful 15.4-point greater improvement in mean Total Improvement Score (TIS) at Week 52 versus placebo (47.95 vs 32.56).
• 2026-08-13 Immunome: Maintaining My ''Strong Buy'' Rating With 2 Catalysts On The Horizon I am maintaining my "Strong Buy" rating on Immunome (IMNM). This decision is driven by FDA acceptance of varegacestat''s NDA and a PDUFA date set for April 2027. The company''s pipeline is diversified, with IM-1021 [ROR1 ADC] in phase 1 for B-cell lymphoma/solid tumors and initial data expected in 2026. The proprietary HC74 TOP1i payload in IM-1021 aims for best-in-class efficacy, targeting resistance and bystander effects beyond Merck''s ROR1 ADC.
• 2026-08-11 Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the quarter ended June 30, 2026, and provided a business update. “We continue to execute against our strategy of building a diversified targeted oncology company with multiple opportunities to bring needed therapies to patients,” said Clay B. Siegall, Ph.D., President and Chief Executive Of.
• 2026-08-06 Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on August 3, 2026, the Compensation Committee of the Company''s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 176,500 shares of common stock to nine new employees under the Company''s 2024 Induc.
• 2026-07-24 Atika Capital Management LLC Sells 71,441 Shares of Immunome, Inc. $IMNM Atika Capital Management LLC lessened its holdings in Immunome, Inc. (NASDAQ: IMNM) by 21.4% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 262,900 shares of the company''s stock after selling 71,441 shares during the quarter. Atika Capital
• 2026-07-20 Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-3050, an FAP-Targeted Radioligand Therapy, in Patients with FAP-Expressing Advanced Solid Tumors BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced that the first patient has been dosed in the Phase 1, first-in-human trial of IM-3050, an investigational FAP-targeted radioligand therapy being evaluated in patients with FAP-expressing advanced solid tumors.“FAP is a high-potential target with expression in 75% of solid tumors,” said Bob Lechleider, M.D., Chi.
• 2026-07-12 What This Immunome Sale Means a Day Before a Big FDA Milestone An Immunome insider sold 100,000 shares for $2.4 million based on weighted average prices on July 6, 2026 and July 7, 2026. The transaction represents 32% of the insider''s total equity holdings in the company.
• 2026-07-10 Immunome Stock Up 32% in a Month: Here''s What You Should Know IMNM jumps 32% in a month. This comes as the FDA accepts varegacestat''s NDA for desmoid tumors, with an approval decision expected by April 2027.
• 2026-07-08 Immunome Announces U.S. FDA Acceptance of New Drug Application for Varegacestat for the Treatment of Adults with Desmoid Tumors BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced the U.S. Food and Drug Administration (FDA or the Agency) has accepted its New Drug Application (NDA) for varegacestat, an investigational, oral, once-daily gamma secretase inhibitor (GSI), for the treatment of adults with desmoid tumors. The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action.